Skip to main content
PMC home page
Frontiers in Nutrition logoLink to Frontiers in Nutrition
. 2023 Oct 5;10:1241848. doi: 10.3389/fnut.2023.1241848

Association of tea and its extracts with colorectal adenomas: meta-analysis and systematic review

Xifei Guan 1, Nawen Liu 1, Zhixin Zhu 1, Yanxue Xu 2, Dehai Xiong 3,*, Xiuyang Li 1,*
PMCID: PMC10585173  PMID: 37867491

Abstract

Background

There are many studies on the association of tea and its extracts with colorectal adenomas, but the results have varied. The study aims to investigate the effect of tea and its extracts on colorectal adenomas using meta analysis and systematic review.

Methods

Literature was obtained through PubMed, Cochrane Library, Embase and Chinese BioMedical Literature Service System since the establishment of the database until April 31, 2023. Search terms include adenomas, polyps, colorectal, rectal, rectum, tea, epigallocatechin, drinking and beverages. Meta-regression analysis was used to infer the source of heterogeneity. Heterogeneity was assessed using I2 statistics and Q test. The effect measures were odds ratio (OR) and 95% confidence interval (95% CI). Stata17.0 software was used for data processing.

Results

The findings indicated that study design (t = 0.78, P = 0.454), types of tea intake (t = 1.35, P = 0.205), occurrences (t = -0.19, P = 0.852), regions (t = 1.13, P = 0.281) and grades of adenomas (t = 0.06, P = 0.952) were statistical homogeneity. Tea and its extracts were negatively correlated with the risk of colorectal adenomas (OR = 0.81, 95% CI: 0.66–0.98). No publication bias was found in this study (t = -0.22, P = 0.828) and the results are robust.

Conclusion

This study suggests that tea and its extracts have a certain protective effect on colorectal adenomas, which provides scientific evidence for preventive strategies for colorectal adenomas. As for the causal relationship between tea and its extracts on colorectal adenomas, further prospective studies are needed.

Keywords: tea, tea extracts, colorectal adenomas, meta-regression, meta-analysis, systematic review

1. Introduction

Colorectal cancer (CRC) is one of the most common malignancies with high incidence and mortality rates (1). According to the information published by the International Agency for Research on Cancer (IARC) of the World Health Organization, CRC was the third most common cancer in the world after lung cancer and breast cancer in terms of global incidence and mortality in 2020 (2). China’s Guideline for the Screening, Early Detection and Early Treatment of CRC points out that the incidence and mortality rates of CRC are on the rise, causing a serious disease burden in China (3). A recent study showed that the burden of CRC increased significantly worldwide over 30 years and that China, the United States and Japan had the highest number of CRC cases in 2019, with East Asia having the highest burden of CRC (4).

Some studies have found that the development of CRC mostly follows the evolutionary pathway of “adenoma-cancer,” that is, normal mucosa first appears with epithelial hyperplasia-like changes, then can gradually transform into an adenoma, and later can develop into carcinoma in situ and invasive carcinoma, and it generally takes 5–10 years to progress from precancerous lesions to cancer, this provides an important time window for early diagnosis and clinical intervention (5–7). Therefore, the development of CRC can be largely prevented by modifying modifiable risk factors and through the detection and removal of precancerous lesions (8).

Tea is rich in polyphenolic compounds, with catechins as the main component. Studies have shown that catechins have a variety of pharmacological properties, including antioxidant, anti-inflammatory, anti-cancer effects, and so on (9–11). In the gastrointestinal tract, green tea has been found to activate intracellular antioxidants, inhibit the formation of carcinogens, angiogenesis and the proliferation of cancer cells (12, 13).

There are few studies investigating the relationship between tea and the risk of colorectal adenomas. Some studies have found that tea has a negative correlation with the risk of colorectal adenomas and helps reduce the incidence of CRC (14, 15). However, the studies were not in agreement, for example, the results of Chen et al. showed a protective effect of tea consumption on low-risk colorectal adenomas (OR = 0.66, 95% CI: 0.48–0.90) and high-risk colorectal adenomas (OR = 0.57, 95% CI: 0.36–0.89) (16), while the results of Budhathoki et al. found no association between tea intake and the risk of colorectal adenomas (OR = 1.50, 95% CI: 0.97–2.31) (17). Therefore, this study is aimed to analyze and evaluate the relationship between tea and its extracts on colorectal adenomas by using meta-analysis, to provide some scientific evidence for the prevention of colorectal adenomas and CRC through tea consumption.

2. Materials and methods

2.1. Search strategy

The systematic review and meta-analysis were performed according to the Cochrane Handbook for Systematic Reviews of Interventions (18) and the Preferred Reporting Items for Systematic Reviews and Meta-Analyzes guidelines for meta-analysis (19). This project was registered with the International Prospective Register of Systematic Reviews (PROSPERO) under registration identification number CRD42023396930 (20), and compliant with the main PRISMA statement (21, 22). Studies related to tea and its extracts with colorectal adenomas were identified by searching PubMed, Cochrane Library, Embase and Chinese BioMedical Literature Service System, all from the time of creation to 31 April 2023. Meanwhile, references of included literature were further manually searched to identify additional studies that met the inclusion criteria.

Research terms (adenomas OR polyps) AND (colorectal OR rectal OR rectum) AND (tea OR epigallocatechin OR drinking OR beverages OR diet) were used. The details of research strategy were provided in Supplementary material. Each identified report was carefully scanned by two of the authors.

2.2. Selection criteria

Inclusion criteria were as follows: (1) literature investigating the relationship between tea and its extracts with colorectal adenomas, (2) cohort studies, case–control studies, cross-sectional studies, or randomized controlled trials (RCTs), (3) studies reporting the definition of colorectal adenomas and the methods of diagnosis, and (4) literature reporting the sample size of the study, or which could be derived from the original data.

Reports as follows were excluded: (1) literature with repeated reports on the same population, (2) case reports, reviews, letters or comments, (3) animal or cell trials, and (4) literature with incomplete data or where sample sizes for each study result could not be derived from the literature.

2.3. Data extraction and quality assessment

Two authors screened the literature independently, extracted information using a uniform data extraction form and cross-checked. In case of disagreement, it was discussed or referred to a third-party evaluation for resolution. Potentially eligible studies were selected by abstracting the title or abstract. If the title or the abstract was inadequate to reach a final decision, the full paper was obtained. Data extraction included: the first author’s name, published year, country, study design, sex ratio, age, cases, sample size, odds ratio (OR) and its 95% confidence interval (95% CI) after adjusting for the most covariates, and adjusted confounders. The Newcastle-Ottawa scale was used to assess the quality and risk of bias of observational studies (23), and studies scoring seven or more than seven were defined as high-quality studies. The Cochrane Collaboration’s tool was used to assess the quality of RCTs (24).

2.4. Statistical analysis

Observational studies collected effect sizes for each study, using the OR and its 95% CI as the effect analysis statistics, and clinical trials performed quantitative pooled analyzes, calculating combined estimates expressed as relative risk (RR) with corresponding 95% CI to test the association between tea and its extracts on the risk of colorectal adenomas. Heterogeneity between studies was assessed using Cochran’s Q test and the I2 statistic (25, 26). Heterogeneity was considered to be significant if I2 > 50% and P ≤ 0.05, and analysis was performed using a random-effect model, conversely, there was no heterogeneity and a fixed-effect mode can be used. Forest plots were produced to show the results of each trial and estimate the overall effect size. Publication bias was assessed using funnel plots and Egger’s test (27). Sensitivity analysis was conducted by omitting one estimate at a time sequentially and recalculating the pooled results to measure the effect of each study on the overall effects and the robustness of the results.

All statistical analyzes were performed by STATA software (Version 17.0, Stata Corporation, College Station, TX, United States). The differences were considered to be statistically significant at P-value ≤0.05 with the two-sided test.

3. Results

3.1. Search results and study characteristics

The literature screening process was shown in Figure 1. In the initial screening process, a total of 4,364 articles were retrieved from the database, after removing duplicate articles, the titles and abstracts of the remaining 3,647 articles were read, and 59 articles were retained after excluding those that did not meet the study criteria. After a full-text review, 47 papers were excluded, and a total of 12 papers were finally included for systematic review and meta-analysis (16, 17, 28–37).

Figure 1.

Figure 1

Open in a new tab

PRISMA flow diagram of the study selection process.

The basic characteristics of the included studies were shown in Table 1. All articles were published between 1990 and 2022, including one cross-sectional study, two cohort studies, five case–control studies, and four RCTs. The risk of bias assessment for the observational studies and RCTs was presented in Supplementary Table S1 and Supplementary Figure S1, respectively. According to the Newcastle-Ottawa scale and the Cochrane collaboration’s tool, the quality of the observational studies was high, and there was no significant risk of bias in the included RCTs.

Table 1.

Characteristics of included studies in the meta-analysis.

Study, year Location Study design a Age b Males/Females Occurrence Cases Control/sample size Type of tea intake Factors/Comparison (highest v.lowest) Results Adjusted confounders
Seufferlein, 2022 Germany RCT 45–80 406/226 Recurrence 338 632 EGCG 300 mg/day v. placebo RR = 0.92
(95% CI: 0.79–1.06)		 Age, low-dose aspirin, center
Chen, 2021 China Cross-sectional study 50.26 ± 11.95 4111/2907 Incidence 670 7,018 Green tea ≥42 cup-year v. none OR = 0.63
(95% CI: 0.49–0.82)		 Age, sex, obesity, smoking, alcohol use, hypertension, diabetes, cholesterol/high-density cholesterol, NSAID use, family history of CRC, regular exercise
Sinicrope, 2021 USA RCT 61.7 ± 8.6 22/10 Recurrence 10 31 EGCG 390 mg/day v. placebo RR = 0.81
(95% CI: 0.28–2.31)		 Age, sex, race, center, history of disease, aspirin use
Shin, 2018 Korea RCT 19–85 97/46 Recurrence 47 143 EGCG 206 mg/day v. placebo RR = 0.56
(95% CI: 0.34–0.92)		 Age, sex, BMI, smoking, alcohol drinking, comorbidities, laboratory findings, baseline colonoscopy findings
Nakamura, 2016 Japan Cohort study 40–65 297/0 Recurrence 164 297 Green tea >6cup/day v. 0cup/day OR = 0.68
(95% CI: 0.26–1.74)		 Age, BMI, physical activity, alcohol consumption, current smoking status, energy intake, dietary fat, dietary fiber, caffeine consumption, fasting serum glucose, and the randomization group from the previous study
Budhathoki, 2015 Japan Case–control study 40–79 951/484 Incidence 738 697 Green tea >960.0 mL/day v. <194.3 mL/day OR = 1.50
(95% CI: 0.97–2.31)		 Age, sex, BMI, smoking, alcohol drinking, screening period, physical activity, parental CRC history, history of diabetes mellitus, NSAID use, total energy, folate, fiber, isoflavone, red and processed meat intake
Shimizul, 2008 Japan RCT 20–80 81/44 Recurrence 29 125 EGCG 157.5 mg/day v. 0 mg/day RR = 0.49
(95% CI: 0.24–0.99)		 Age, sex, tea consumption, number, size and histological grading of initial adenomas
Il’yasova, 2003 USA Case–control study 30–80 196/298 Incidence 171 323 Black tea >3servings/day v. <2servings/day OR = 0.50
(95% CI: 0.20–1.10)		 Age, sex, BMI, race, apoptotic score
Baron, 1997 USA Cohort study 61.3 ± 8.3 520/146 Recurrence 243 666 Black tea ≥1cup/day v. 0cup/day OR = 1.29
(95% CI: 0.75–2.22)		 Age, sex, smoking, alcohol intake, center, colonoscopy interval, total caloric intake, dietary fat, dietary fiber
Olsen, 1993 Denmark Case–control study 45–74 214/319 Incidence 171 362 Black tea ≥4 cup/day v. 0–3 cup/day OR = 1.30
(95% CI: 0.70–2.30)		 Age, sex, dietary fiber
Kono, 1991 Japan Case–control study 49–56 1228/0 Incidence 80 1,148 Green tea ≥5 cups/day v. <3 cups/day OR = 0.69
(95% CI: 0.61–1.95)		 Smoking, alcohol drinking, physical activity
Kato, 1990 Japan Case–control study 35–80 716/387 Incidence 525 578 Green tea and Black tea ≥1cup/day v. <1cup/day Green tea: OR = 0.63 (95% CI: 0.50–0.79); Black tea: OR = 0.95 (95% CI: 0.55–1.63) Age, sex, residence
Open in a new tab
a

If studies reported results from the same population and their investigated factors overlapped, the most recent publications or studies with the biggest sample size were used for meta-analysis.

b

The age variable was described in terms of mean (standard deviation) or age range.

BMI, body mass index; CRC, colorectal cancer; EGCG, epigallocatechin gallate; NSAID, non-steroidal anti-inflammatory drug; RCT, randomized controlled trial.

3.2. Effects of tea and its extracts on the colorectal adenomas

The results of the overall meta-analysis were presented in Figure 2. The heterogeneity test showed the existence of heterogeneity between studies (I2 = 60.3%, P = 0.003), so a random-effect model was used for the analysis. The results indicated that tea and its extracts could reduce the risk of colorectal adenomas (OR = 0.81, 95% CI: 0.66–0.98).

Figure 2.

Figure 2

Open in a new tab

Forest plot of tea and its extracts with colorectal adenomas.

3.3. Meta-regression and subgroup analysis

Meta-regression analysis was conducted according to two study design types, observational studies and clinical trials, two types of tea intake, green and black tea, two occurrences, incidence and recurrence, three regions, East Asia, North America, and Europe, and two grades of adenomas, low and high. The results were presented in Table 2, which showed that there was no heterogeneity between study design types, types of tea intake, occurrences, regions and grades of adenomas.

Table 2.

Results of univariate meta-regression analysis.

Covariates Coefficient SE t-value P-value
Study design 0.1860 0.2397 0.78 0.454
Type of tea intake 0.3099 0.2302 1.35 0.205
Occurrence −0.0427 0.2233 −0.19 0.852
Region 0.1545 0.1361 1.13 0.281
Grade of adenomas 0.0165 0.2581 0.06 0.952
Open in a new tab

The results of the subgroup analysis were presented in Supplementary Table S2 and Supplementary Figure S2. The association was significant in green tea (OR = 0.75, 95% CI: 0.60–0.93), while there was no association between black tea and colorectal adenomas (OR = 1.03, 95% CI: 0.72–1.47). Subgroup analysis based on region indicated that tea and its extracts reduced the risk of colorectal adenomas by 27% (95% CI: 0.57–0.92) in East Asia, while results showed that tea and its extracts were not associated with colorectal adenomas in North America (OR = 0.87, 95% CI: 0.48–1.59) and Europe (OR = 0.97, 95% CI: 0.76–1.22). The association was more significant between tea and its extracts with low-risk colorectal adenomas (OR = 0.74, 95% CI: 0.57–0.95), but not with the risk of high-risk colorectal adenomas (OR = 0.73, 95% CI: 0.47–1.14).

3.4. Publication bias and sensitivity analysis

Funnel plots of the studies were shown in Figure 3. Visual inspection was largely symmetrical, and the results of Egger’s test also showed that there was no publication bias (t = −0.22, P = 0.828). The results of sensitivity analysis showed no impact of excluding any single study on the overall estimate of the effect of tea and its extracts on the risk of colorectal adenomas, indicating that the analysis was robust (Figure 4; Table 3).

Figure 3.

Figure 3

Open in a new tab

The funnel plot of included studies.

Figure 4.

Figure 4

Open in a new tab

Sensitivity analyzes by omitting one study at a time.

Table 3.

The results of sensitivity analyzes.

Study omitted OR 95% CI
Seufferlein, 2022 0.79 0.63–0.98
Chen, 2021 0.83 0.68–1.03
Sinicrope, 2021 0.81 0.66–0.98
Shin, 2018 0.83 0.68–1.01
Nakamura, 2016 0.81 0.66–0.99
Budhathoki, 2015 0.76 0.63–0.91
Shimizul, 2008 0.83 0.68–1.01
Il’yasova, 2003 0.82 0.67–0.99
Baron, 1997 0.78 0.64–0.94
Olsen, 1993 0.78 0.64–0.95
Kono, 1991 0.81 0.66–0.99
Kato, 1990Green tea 0.84 0.68–1.03
Kato, 1990Black tea 0.80 0.65–0.98
Combined 0.81 0.66–0.98
Open in a new tab

4. Discussion

This meta-analysis and systematic review is the latest study investigating tea and its extracts and their influence on the risk of colorectal adenomas. The meta-analysis of 12 studies indicates that tea and tea extract supplements have a protective effect against colorectal adenomas.

Tea originated from the plant species Camellia sinensis and has become the second most commonly consumed beverage in the world, with green tea, black tea and oolong tea being among the beverages often consumed (38). Tea is rich in many active ingredients, the main component of polyphenols, which has been proven in animal and cellular experiments to inhibit the formation and proliferation of CRC and other tumors (39, 40). Different types of tea contain different types and contents of polyphenols, theaflavin-3, 30-digallate (TFDG) in black tea and epigallocatechin-3-O-gallate (EGCG) in green tea have a protective effect against oxidative stress, these substances are involved in many biochemical processes responsible for the inflammation and proliferation of cancer cells, all of which reduce the phenomenon and symptoms of intestinal inflammation, reduce the proliferation of intestinal polyps and adenomas and reduce the proliferation of CRC cells (41–44).

Chen et al. (45) reported a meta-analysis on the association between tea consumption and CRC, which enrolled cohort studies and case–control studies. The results among all studies showed that compared with the lowest tea consumption, the highest tea consumption reduced the risk of CRC by 7% (OR = 0.93, 95% CI: 0.87–1.00), indicating that tea consumption had an effect on the prevention of colorectal tumors, which was consistent with the results of our study. However, a meta-analysis of case–control studies showed that high-dose green tea intake may marginally reduce the risk of colorectal tumors, without statistical significance (OR = 0.95, 95% CI: 0.81–1.11) (46); another meta-analysis based on prospective cohort studies also showed no significant association between tea consumption and colorectal tumor risk (RR = 0.97, 95% CI: 0.94–1.01) (47), which was similar to the results of the former study.

The results of subgroup analyzes showed a protective effect of green tea and its extracts against colorectal adenomas, as well as in East Asian populations. This may be due to the prevalence of tea culture in Asia, where the content and frequency of tea drinking are much higher than those in North America and Europe. Moreover, green tea is mostly consumed in Asia, while black tea is mostly consumed in North America and Europe. This result is consistent with the results of the subgroup analysis of tea intake types in the previous section. Chen et al. also reported that significant correlations were observed in the green tea and CRC in their meta-analysis (45), which was similar to our findings. In a meta-analysis based on case–control studies, Wang et al. (46) found that tea had an insignificant protective effect against colorectal tumors in Asia (OR = 0.87, 95% CI: 0.62–1.22) in addition to the US and European populations, whereas the results of our study showed that tea had a pronounced protective effect against colorectal adenomas in East Asian populations. In terms of adenomas grade, the results showed that tea and its extracts reduced the risk of low-risk colorectal adenomas (OR = 0.74, 95% CI: 0.57–0.95), but were not correlated with the risk of high-risk colorectal adenomas (OR = 0.73, 95% CI: 0.47–1.14). However, only three of the included studies graded the adenomas, so the results may be biased. Chen et al. showed that tea consumption ≥42 cup-years reduced the incidence of low-risk adenomas (OR = 0.66, 95% CI: 0.48–0.90) and high-risk adenomas (OR = 0.57, 95% CI: 0.36–0.89), but when tea consumption <42 cup-years, it only had a protective effect against low-risk adenomas, not between high-risk adenomas (16). Meanwhile, Nakachi et al. (48) found that the incidence of CRC was lower among patients who consumed more than 10 cups of green tea per day. Since no significant differences were observed in subjects who consumed less than 10 cups per day, there may be a threshold amount of tea protection, and the threshold for high-risk adenomas was higher than that for low-risk adenomas. Other factors such as subject selection bias, diet, alcohol consumption, smoking (49), type of tea, total tea consumption, measurement error (50), and temperature of tea infusion may also affect the study results.

The strength of this study is that we enrolled all relevant studies (n = 12), with a larger proportion of RCT studies and cohort studies, and a higher level of confidence in the results of the analysis. Besides, we performed relatively comprehensive analyzes including meta-regression analysis, subgroup analysis, publication bias detection, and sensitivity analysis to explore potential sources of heterogeneity and bias.

However, our study still has several limitations. Firstly, the number of enrolled studies was limited, so the number of literature on the subgroup analysis groups was fewer, and their results may be unstable. Secondly, there is the issue of measurement error, which may result in bias in the calculation of estimated effects and the judgment of confounding factors due to different methods of measuring the dosage of tea and its extracts included in the study. Finally, because tea is mainly prevalent in Asia, the relatively large sample size of Asians in this study leads to a potential selection bias, caution should be exercised when extrapolating the results of this study to other countries. More studies are needed to confirm the preventive effect of tea on the risk of colorectal adenomas, especially for populations of different genders in different regions.

5. Conclusion

The result from the meta-analysis of 12 studies indicates that tea and its extract supplements have a protective effect against colorectal adenomas. Subgroup analyzes show that the protective effects of tea and its extracts against colorectal adenomas are more pronounced in green tea, East Asian populations, and low-risk adenomas, but the number of literature on the subgroup analysis groups was fewer, which needs to be determined by more evidence. The findings may provide a theoretical basis for the development of nutrition guidelines. As for the causal relationship between tea and its extracts on colorectal adenomas, further prospective studies are needed.

Author contributions

XL, DX, and XG conceived and designed the meta-analysis. XG, NL, ZZ, and YX searched the literature. XG, NL, and ZZ extracted the data. XG analyzed the data. ZZ contributed analysis tools. XG and NL wrote the manuscript. XL revised the manuscript. All authors contributed to the article and approved the submitted version.

Glossary

Abbreviations

CI

Confidence interval

CRC

Colorectal cancer

EGCG

Epigallocatechin-3-O-gallate

IARC

International Agency for Research on Cancer

OR

Odds ratio

RCTs

Randomized controlled trials

RR

Relative risk

TFDG

Theaflavin-3, 30-digallate

Funding Statement

This work was supported by scientific research Foundation of China Human Health Science and Technology Promotion Association.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fnut.2023.1241848/full#supplementary-material

Click here for additional data file. (539.5KB, pdf)

References

  • 1.Baidoun F, Elshiwy K, Elkeraie Y, Merjaneh Z, Khoudari G, Sarmini MT, et al. Colorectal Cancer epidemiology: recent trends and impact on outcomes. Curr Drug Targets. (2021) 22:998–1009. doi: 10.2174/1389450121999201117115717, PMID: [DOI] [PubMed] [Google Scholar]
  • 2.Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer statistics 2020: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. (2021) 71:209–49. doi: 10.3322/caac.21660 [DOI] [PubMed] [Google Scholar]
  • 3.Expert Group of the Development of China Guideline for the Screening EDaEToCC . China guideline for the screening, early detection and early treatment of colorectal Cancer (2020, Beijing). Zhonghua Zhong Liu Za Zhi. (2021) 43:16–38. doi: 10.3760/cma.j.cn112152-20210105-00010 [DOI] [PubMed] [Google Scholar]
  • 4.Collaborators GBDCC . Global, regional, and National Burden of colorectal Cancer and its risk factors, 1990-2019: a systematic analysis for the global burden of disease study 2019. Lancet Gastroenterol Hepatol. (2022) 7:627–47. doi: 10.1016/S2468-1253(22)00044-9, PMID: [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Hale VL, Chen J, Johnson S, Harrington SC, Yab TC, Smyrk TC, et al. Shifts in the fecal microbiota associated with adenomatous polyps. Cancer Epidemiol Biomarkers Prev. (2017) 26:85–94. doi: 10.1158/1055-9965.EPI-16-0337 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Peters BA, Dominianni C, Shapiro JA, Church TR, Wu J, Miller G, et al. The gut microbiota in conventional and serrated precursors of colorectal Cancer. Microbiome. (2016) 4:69. doi: 10.1186/s40168-016-0218-6, PMID: [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Dekker E, Tanis PJ, Vleugels JLA, Kasi PM, Wallace MB. Colorectal Cancer. Lancet. (2019) 394:1467–80. doi: 10.1016/S0140-6736(19)32319-0 [DOI] [PubMed] [Google Scholar]
  • 8.Morgan E, Arnold M, Gini A, Lorenzoni V, Cabasag CJ, Laversanne M, et al. Global burden of colorectal Cancer in 2020 and 2040: incidence and mortality estimates from Globocan. Gut. (2023) 72:338–44. doi: 10.1136/gutjnl-2022-327736, PMID: [DOI] [PubMed] [Google Scholar]
  • 9.Zhao T, Li C, Wang S, Song X. Green tea (Camellia Sinensis): a review of its Phytochemistry, pharmacology, and toxicology. Molecules. (2022) 27:27(12). doi: 10.3390/molecules27123909, PMID: [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Balazi A, Sirotkin AV, Foldesiova M, Makovicky P, Chrastinova L, Makovicky P, et al. Green tea can Supress rabbit ovarian functions in vitro and in vivo. Theriogenology. (2019) 127:72–9. doi: 10.1016/j.theriogenology.2019.01.010, PMID: [DOI] [PubMed] [Google Scholar]
  • 11.Lambert JD, Elias RJ. The antioxidant and pro-oxidant activities of green tea polyphenols: a role in Cancer prevention. Arch Biochem Biophys. (2010) 501:65–72. doi: 10.1016/j.abb.2010.06.013, PMID: [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Koo MW, Cho CH. Pharmacological effects of green tea on the gastrointestinal system. Eur J Pharmacol. (2004) 500:177–85. doi: 10.1016/j.ejphar.2004.07.023 [DOI] [PubMed] [Google Scholar]
  • 13.Berger SJ, Gupta S, Belfi CA, Gosky DM, Mukhtar H. Green tea constituent (−-)-Epigallocatechin-3-Gallate inhibits topoisomerase I activity in human Colon carcinoma cells. Biochem Biophys Res Commun. (2001) 288:101–5. doi: 10.1006/bbrc.2001.5736 [DOI] [PubMed] [Google Scholar]
  • 14.Kris-Etherton PM, Hecker KD, Bonanome A, Coval SM, Binkoski AE, Hilpert KF, et al. Bioactive compounds in foods: their role in the prevention of cardiovascular disease and Cancer. Am J Med. (2002) 113:71–88. doi: 10.1016/S0002-9343(01)00995-0 [DOI] [PubMed] [Google Scholar]
  • 15.Fujiki H. Chemoprevention of Cancer. Gan to kagaku ryoho Cancer & chemotherapy. (1986) 13:3384–91. [PubMed] [Google Scholar]
  • 16.Chen HY, Sun ZJ, Li CH, Chou YT, Chang CJ, Lu FH, et al. Cumulative tea consumption is inversely associated with colorectal adenomas in adults: a cross-sectional study in a Taiwanese population. Cancer Epidemiol. (2021) 73:101945. doi: 10.1016/j.canep.2021.101945 [DOI] [PubMed] [Google Scholar]
  • 17.Budhathoki S, Iwasaki M, Yamaji T, Sasazuki S, Tsugane S. Coffee intake and the risk of colorectal adenoma: the colorectal adenoma study in Tokyo. Int J Cancer. (2015) 137:463–70. doi: 10.1002/ijc.29390, PMID: [DOI] [PubMed] [Google Scholar]
  • 18.Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1. Hoboken, NJ: Wiley; (2008). [Google Scholar]
  • 19.Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, et al. The Prisma statement for reporting systematic reviews and Meta-analyzes of studies that evaluate health care interventions: explanation and elaboration. PLoS Med. (2009) 6:e1000100. doi: 10.1371/journal.pmed.1000100, PMID: [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Booth A, Clarke M, Dooley G, Ghersi D, Moher D, Petticrew M, et al. The nuts and bolts of Prospero: an international prospective register of systematic reviews. Syst Rev. (2012) 1:2. doi: 10.1186/2046-4053-1-2, PMID: [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Stewart LA, Clarke M, Rovers M, Riley RD, Simmonds M, Stewart G, et al. Preferred reporting items for systematic review and Meta-analyses of individual participant data: the Prisma-Ipd statement. JAMA. (2015) 313:1657–65. doi: 10.1001/jama.2015.3656 [DOI] [PubMed] [Google Scholar]
  • 22.Moher D, Liberati A, Tetzlaff J, Altman DG, Group P . Preferred reporting items for systematic reviews and Meta-analyses: the Prisma statement. PLoS Med. (2009) 6:e1000097. doi: 10.1371/journal.pmed.1000097, PMID: [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Wells G, Shea B, O'Connell D, Peterson J, Welch V, Losos M, et al.. The Newcastle-Ottawa Scale (Nos) for Assessing the Quality of Nonrandomised Studies in Meta-Analyses. Available at: https://wwwohrica/programs/clinical_epidemiology/oxfordasp
  • 24.Cumpston M, Li T, Page MJ, Chandler J, Welch VA, Higgins JP, et al. Updated guidance for trusted systematic reviews: a new edition of the Cochrane handbook for systematic reviews of interventions. Cochrane Database Syst Rev. (2019) 10:ED000142. doi: 10.1002/14651858.ED000142, PMID: [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Higgins JP, Thompson SG. Quantifying heterogeneity in a Meta-analysis. Stat Med. (2002) 21:1539–58. doi: 10.1002/sim.1186, PMID: [DOI] [PubMed] [Google Scholar]
  • 26.Ioannidis JP, Patsopoulos NA, Evangelou E. Uncertainty in heterogeneity estimates in Meta-analyses. BMJ. (2007) 335:914–6. doi: 10.1136/bmj.39343.408449.80 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Egger M, Davey Smith G, Schneider M, Minder C. Bias in Meta-analysis detected by a simple, graphical test. BMJ. (1997) 315:629–34. doi: 10.1136/bmj.315.7109.629, PMID: [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Shin CM, Lee DH, Seo AY, Lee HJ, Kim SB, Son WC, et al. Green tea extracts for the prevention of Metachronous colorectal polyps among patients who underwent endoscopic removal of colorectal adenomas: a randomized clinical trial. Clin Nutr. (2018) 37:452–8. doi: 10.1016/j.clnu.2017.01.014, PMID: [DOI] [PubMed] [Google Scholar]
  • 29.Shimizu M, Fukutomi Y, Ninomiya M, Nagura K, Kato T, Araki H, et al. Green tea extracts for the prevention of Metachronous colorectal adenomas: a pilot study. Cancer Epidemiol Biomarkers Prev. (2008) 17:3020–5. doi: 10.1158/1055-9965.EPI-08-0528, PMID: [DOI] [PubMed] [Google Scholar]
  • 30.Il'yasova D, Hodgson ME, Martin C, Galanko J, Sandler RS. Tea consumption, apoptosis, and colorectal adenomas. Eur J Cancer Prev. (2003) 12:439–43. doi: 10.1097/00008469-200310000-00016, PMID: [DOI] [PubMed] [Google Scholar]
  • 31.Baron JA, Robert Greenberg E, Haile R, Mandel J, Sandier RS, Mott L. Coffee and tea and the risk of recurrent colorectal adenomas. Cancer Epidemiol Biomarkers Prev. (1997) 6:7–10. [PubMed] [Google Scholar]
  • 32.Olsen J, Kronborg O. Coffee, tobacco and alcohol as risk factors for Cancer and adenoma of the large intestine. Int J Epidemiol. (1993) 22:398–402. doi: 10.1093/ije/22.3.398, PMID: [DOI] [PubMed] [Google Scholar]
  • 33.Kono S, Shinchi K, Ikeda N, Yanai F, Imanishi K. Physical activity, dietary habits and adenomatous polyps of the sigmoid Colon: a study of self-defense officials in Japan. J Clin Epidemiol. (1991) 44:1255–61. doi: 10.1016/0895-4356(91)90158-6 [DOI] [PubMed] [Google Scholar]
  • 34.Kato I, Tominaga S, Matsuura A, Yoshii Y, Shirai M, Kobayashi S. A comparative case-control study of colorectal Cancer and adenoma. Jpn J Cancer Res. (1990) 81:1101–8. doi: 10.1111/j.1349-7006.1990.tb02520.x, PMID: [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Nakamura T, Ishikawa H, Mutoh M, Wakabayashi K, Kawano A, Sakai T, et al. Coffee prevents proximal colorectal adenomas in Japanese men: a prospective cohort study. Eur J Cancer Prev. (2016) 25:388–94. doi: 10.1097/cej.0000000000000203, PMID: [DOI] [PubMed] [Google Scholar]
  • 36.Seufferlein T, Ettrich TJ, Menzler S, Messmann H, Kleber G, Zipprich A, et al. Green tea extract to prevent colorectal adenomas, results of a randomized, placebo-controlled clinical trial. Am J Gastroenterol. (2022) 117:884–94. doi: 10.14309/ajg.0000000000001706, PMID: [DOI] [PubMed] [Google Scholar]
  • 37.Sinicrope FA, Viggiano TR, Buttar NS, Wong Kee Song LM, Schroeder KW, Kraichely RE, et al. Randomized phase ii trial of Polyphenon E versus placebo in patients at high risk of recurrent colonic neoplasia. Cancer Prev Res. (2021) 14:573–80. doi: 10.1158/1940-6207.CAPR-20-0598, PMID: [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Sharma P, Montes de Oca MK, Alkeswani AR, McClees SF, Das T, Elmets CA, et al. Tea polyphenols for the prevention of Uvb-induced skin Cancer. Photodermatol Photoimmunol Photomed. (2018) 34:50–9. doi: 10.1111/phpp.12356, PMID: [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Wang ST, Cui WQ, Pan D, Jiang M, Chang B, Sang LX. Tea polyphenols and their Chemopreventive and therapeutic effects on colorectal Cancer. World J Gastroenterol. (2020) 26:562–97. doi: 10.3748/wjg.v26.i6.562, PMID: [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Hazafa A, Rehman KU, Jahan N, Jabeen Z. The role of polyphenol (flavonoids) compounds in the treatment of Cancer cells. Nutr Cancer. (2020) 72:386–97. doi: 10.1080/01635581.2019.1637006 [DOI] [PubMed] [Google Scholar]
  • 41.Carini F, Tomasello G, Jurjus A, Geagea A, Al Kattar S, Damiani P, et al. Colorectal Cancer and inflammatory bowel diseases: effects of diet and antioxidants. J Biol Regul Homeost Agents. (2017) 31:791–5. PMID: [PubMed] [Google Scholar]
  • 42.Lecumberri E, Dupertuis YM, Miralbell R, Pichard C. Green tea polyphenol Epigallocatechin-3-Gallate (Egcg) as adjuvant in Cancer therapy. Clin Nutr. (2013) 32:894–903. doi: 10.1016/j.clnu.2013.03.008, PMID: [DOI] [PubMed] [Google Scholar]
  • 43.Jung YD, Kim MS, Shin BA, Chay KO, Ahn BW, Liu W, et al. Egcg, a major component of green tea, inhibits tumour growth by inhibiting Vegf induction in human Colon carcinoma cells. Br J Cancer. (2001) 84:844–50. doi: 10.1054/bjoc.2000.1691, PMID: [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.Konarikova K, Jezovicova M, Kerestes J, Gbelcova H, Durackova Z, Zitnanova I. Anticancer effect of black tea extract in human Cancer cell lines. Springerplus. (2015) 4:127. doi: 10.1186/s40064-015-0871-4, PMID: [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.Chen Y, Wu Y, Du M, Chu H, Zhu L, Tong N, et al. An inverse association between tea consumption and colorectal Cancer risk. Oncotarget. (2017) 8:37367–76. doi: 10.18632/oncotarget.16959, PMID: [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46.Wang XJ, Zeng XT, Duan XL, Zeng HC, Shen R, Zhou P. Association between green tea and colorectal Cancer risk: a Meta-analysis of 13 case-control studies. Asian Pac J Cancer Prev. (2012) 13:3123–7. doi: 10.7314/apjcp.2012.13.7.3123 [DOI] [PubMed] [Google Scholar]
  • 47.Zhu MZ, Lu DM, Ouyang J, Zhou F, Huang PF, Gu BZ, et al. Tea consumption and colorectal Cancer risk: a Meta-analysis of prospective cohort studies. Eur J Nutr. (2020) 59:3603–15. doi: 10.1007/s00394-020-02195-3, PMID: [DOI] [PubMed] [Google Scholar]
  • 48.Nakachi K, Matsuyama S, Miyake S, Suganuma M, Imai K. Preventive effects of drinking green tea on Cancer and cardiovascular disease: epidemiological evidence for multiple targeting prevention. Biofactors. (2000) 13:49–54. doi: 10.1002/biof.5520130109, PMID: [DOI] [PubMed] [Google Scholar]
  • 49.Lambert JD, Yang CS. Cancer Chemopreventive activity and bioavailability of tea and tea polyphenols. Mutat Res. (2003) 523-524:201–8. doi: 10.1016/s0027-5107(02)00336-6, PMID: [DOI] [PubMed] [Google Scholar]
  • 50.Imai K, Suga K, Nakachi K. Cancer-preventive effects of drinking green tea among a Japanese population. Prev Med. (1997) 26:769–75. doi: 10.1006/pmed.1997.0242, PMID: [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Click here for additional data file. (539.5KB, pdf)

Articles from Frontiers in Nutrition are provided here courtesy of Frontiers Media SA

RESOURCES